-
1. Caribou Biosciences | Developing Sophisticated Allogeneic Cell …
Link: https://www.cariboubio.com/
Description: WEBCaribou Biosciences | Developing Sophisticated Allogeneic Cell Therapies. We are a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases. Precision genome editing.
-
2. Leadership | Board of Directors | SAB | Caribou Biosciences
Link: https://www.cariboubio.com/about/
Description: WEBCaribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing. We use our novel, next-generation CRISPR genome-editing technology to armor allogeneic, or off-the-shelf, cell therapies for potentially improved antitumor activity.
-
3. Pipeline | CB-010 | CB-011 | CB-012 | CB-020 | Caribou Biosciences
Link: https://www.cariboubio.com/pipeline/
Description: WEBCaribou Biosciences is developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for a range of tumor types.
-
4. Caribou Biosciences Expands Clinical Development of CB-010 …
Link: https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-expands-clinical-development-cb-010-fda
Description: WEBApr 4, 2024 · Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus. April 4, 2024. PDF Version. -- FDA has cleared Caribou’s IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-
5. Press releases | Caribou Biosciences, Inc.
Link: https://investor.cariboubio.com/news-events/press-releases
Description: WEBApr 4, 2024 · Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus. PDF Version. March 11, 2024. Caribou Biosciences …
-
6. Investors | Caribou Biosciences, Inc.
Link: https://investor.cariboubio.com/
Description: WEBApr 4, 2024 · Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its patented Cas12a chRDNA technology, enables superior precision to develop cell therapies that …
-
7. Allogeneic T cells and NK cells | chRDNAs | Caribou Biosciences
Link: https://www.cariboubio.com/technology/
Description: WEBAllogeneic T cells and NK cells | chRDNAs | Caribou Biosciences. Off-the-shelf CAR-T cell therapies. CAR-T cell therapies have shown great promise in treating blood cancers and autoimmune diseases.
-
8. Caribou Biosciences Announces Oral Presentation on In Vivo …
Link: https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-oral-presentation-vivo-cas12a
Description: WEBApr 15, 2024 · Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are …
-
9. Caribou Biosciences Announces the FDA Granted Regenerative
Link: https://www.globenewswire.com/news-release/2022/11/29/2564105/0/en/Caribou-Biosciences-Announces-the-FDA-Granted-Regenerative-Medicine-Advanced-Therapy-RMAT-and-Fast-Track-Designations-to-CB-010-an-Allogeneic-Anti-CD19-CAR-T-Cell-Therapy.html
Description: WEBBERKELEY, CA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the U.S....
-
10. Caribou Biosciences Announces Closing of Upsized Initial Public
Link: https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-closing-upsized-initial-public/
Description: WEBJul 23, 2021 · Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company’s proprietary chRDNA technology toward the development of next-generation, genome-edited allogeneic immune cell therapies.
